Loading...
Loading...
SLN| Name | Value |
|---|---|
| Revenues | 9.1M |
| Cost of Revenue | 2.8M |
| Gross Profit | 6.3M |
| Operating Expense | 17.7M |
| Operating I/L | -11.5M |
| Other Income/Expense | -0.6M |
| Interest Income | 0.3M |
| Pretax | -12.0M |
| Income Tax Expense | -1.6M |
| Net Income/Loss | -10.4M |
Silence Therapeutics plc is a biotechnology company specializing in the discovery and development of RNA therapeutics for hematology, cardiovascular, and rare metabolic indications. The company's mRNAi GalNAc Oligonucleotide Discovery platform targets disease-associated genes in the liver by designing short interfering RNA molecules. Its product candidates include SLN360 and SLN124, currently in Phase I clinical trials for cardiovascular disease, thalassemia, myelodysplastic syndrome, and polycythemia vera. Silence Therapeutics has collaboration agreements with AstraZeneca PLC, Mallinckrodt Pharma IP Trading DAC, and Hansoh Pharmaceutical Group Company Limited to develop and commercialize RNAi drug targets for various diseases.
